Amgen will offer its lipid-lowering drug Repatha directly to patients for $239 per month, representing a nearly 60% reduction ...
GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the availability of Repatha® ...
Amgen announced the launch of its direct-to-patient program providing eligible patients discounted pricing for evolocumab, a ...
Pharmaceutical Technology on MSN
Amgen’s Phase III data supports FDA label expansion of Repatha
Amgen received a label expansion from the FDA in August 2025, with the VESALIUS-CV data supporting this decision.
Findings from the Phase III VESALIUS-CV study reinforce the cholesterol-lowering benefit of Repatha in high-risk patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback